18 September 20102011 Prohibited List
Explanatory Notes on the 2011 Prohibited List:
Introduction
Members of the Anti-Doping Community should be aware that carefulconsideration has been given to all of the thoughtful comments that havebeen provided in response to the distribution of the draft 2011 List. It will
be recognized that not all suggestions have been accepted or incorporated
into the 2011 List but, as is explained below, modifications to the draft
have been made possible because of the contributions and submissions ofmany of our colleagues.

S0 NON-APPROVED SUBSTANCES AND METHODSThis section has been added in order to address the issue of the abuse ofsubstances that are currently in an experimental phase of development or that are
not or no longer permitted for human use.

S1 ANABOLIC AGENTS
This section has been modified in a minor way to standardize the spelling for
certain substances.

S2 PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES
S2.1: This section has been modified to include the international nonproprietary name of Hematide – “peginesatide”. In order to reflect the growing
Explanatory Notes
18 September 2010

number of substances developed to stimulate erythropoiesis, hypoxia-inducible
factor (HIF)-stabilizers have been added as an example of this class of products.
S2.3: Questions relating to the use of insulins and other associated substances
will be the focus of further review by the List Expert Group in 2011.
S2.6: Platelet-derived preparations have been removed from the List after
consideration of the lack of any current evidence concerning the use of thesemethods for purposes of performance enhancement notwithstanding that these
preparations contain growth factors Despite the presence of some growthfactors, current studies on PRP do not demonstrate any potential for
performance enhancement beyond a potential therapeutic effect. Note that
individual growth factors are still prohibited when given separately as purified
substances as described in S.2.5
S3BETA-2-AGONISTSThe WADA List Expert Group made changes to S3 (beta-2-agonists) in response tothe concerns expressed by members of the Sport Community. References to the“Declaration of Use” have been removed. Concerns continue to exist about theperformance-enhancing effects of beta-2-agonists when taken in large quantities.
The List prohibits the administration of all beta-2-agonists except salbutamol(maximum 1600 micrograms over 24 hours) and salmeterol when taken byinhalation in accordance with the recommended therapeutic regime. Urinary
thresholds continue to apply to the management of salbutamol; work is ongoing todevelop thresholds for other beta-2-agonists.
The issue of beta-2-agonists will continue to be the focus of WADA’s research
activity in order to ensure that the administration of large doses of thesesubstances is prevented and prohibited, but that the appropriate care andtreatment of asthmatic athletes is facilitated. Ongoing surveillance of the use of
these medications will continue as a priority; it is to be anticipated that there will befurther changes in the way in which these substances are addressed in the future.

S5 DIURETICS AND OTHER MASKING AGENTS.
• The prohibition of glycerol is not intended to prevent the ingestion of thissubstance which is commonly found in a variety of foodstuffs and toiletries. Suchuse will not cause a competitor to test positive for this Prohibited Substance.
Explanatory Notes18 September 2010• “Desmopressin” has been added as an example of a masking agent.
• The last paragraph of section S5 has been revised to more clearly explain theconsequences of detecting an exogenous threshold substance at a sub-thresholdconcentration in the presence of a diuretic or other masking agent. Even when a
Therapeutic Use Exemption (TUE) exists for the masking agent, the detection ofthe exogenous threshold substance at any level will be reported as an Adverse
Analytical Finding by the laboratory and therefore a TUE is also required for thethreshold substance when applicable.
M1 ENHANCEMENT OF OXYGEN TRANSFER
Minor changes have been made to the wording of this section to ensure consistencyof style and structure.

M2 CHEMICAL AND PHYSICAL MANIPULATION
M2.2: Attention is drawn to the fact that medical information is provided on theWADA Web site (http://www.wadaama.org/Documents/Science_Medicine/Medical_info_to_support_TUECs/WADA_Med
ical_info_IV_infusions_v.2.2_March2010_EN.pdf) to support the decisions of TUECs
regarding the use of intravenous infusions.
M2.3: The prohibition of “the sequential withdrawal, manipulation, and reinfusionof whole blood” is not intended to prevent plasmapheresis, a specialized form ofblood donation, and similar processes which are often undertaken by civic-minded
Athletes and do not involve the re-administration of whole blood; rather it
specifically addresses the process in which an Athlete’s blood is removed, treated ormanipulated, and then re-injected. Those undergoing hemodialysis, as part of thetreatment of chronic kidney disease, will require a TUE for such procedures (andthe substances that are often used to treat such disorders).

M3GENE DOPING

Significant changes have occurred to the wording, and ordering, of this section for
purposes of clarification.

Explanatory Notes
18 September 2010

S6 STIMULANTS• The stimulant “methylhexaneamine” (which may be described, like many othersubstances, by other chemical names) is now included in the Prohibited List as aSpecified Substance. This substance is now often marketed as a nutritional
supplement and may frequently be referred to as “geranium oil” or “geranium
root extract”.
• Minor changes have been made to the spelling of “levmetamfetamine”.
S8 CANNABINOIDS
There have been changes to this section to clarify that marijuana-like substances(cannabimimetics) are included in the List.

S9 GLUCOCORTICOSTEROIDS
The section remains unchanged from the 2010 List insofar as the prohibited routesof administration of glucocorticosteroids are concerned. Surveillance of the use of
these substances continues and work is ongoing to develop threshold levels toassist in the detection and management of these substances. It is to be anticipatedthat there will be further changes in this section in the future. References to“Declarations of Use” and “Therapeutic Use Exemptions” have been removed.

P1 ALCOHOL
Changes have been made in response to requests by the Union Internationale dePentathlon Moderne (UIPM); due to changes introduced in the format of thecompetition, alcohol is no longer prohibited in Modern Pentathlon for disciplines
involving shooting.
P2 BETA-BLOCKERS• For clarification purposes, Skeleton has been added by name to the list ofFédération Internationale de Bobsleigh et de Tobogganing (FIBT)-governed sports
where beta-blockers are prohibited.
• At the request of the federation [Fédération Internationale de Gymnastique (FIG)]
beta-blockers are no longer prohibited in gymnastics.
• At the request of the federation [World Darts Federation (WDF)] beta-blockers
are now prohibited in the sport of darts.
Explanatory Notes
18 September 2010